194
Views
16
CrossRef citations to date
0
Altmetric
Original Article

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study

, , , , , & show all
Pages 1417-1428 | Accepted 11 Mar 2008, Published online: 08 Apr 2008

References

  • Bjork S. The cost of diabetes and diabetes care. Diabetes Res Clin Pract 2001;54(Suppl 1):S13–18
  • Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens 2000;14:667–85
  • Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002;45:S5–12
  • The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86
  • The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53
  • Luddeke HJ, Sreenan S, Aczel S, et al. PREDICTIVE – a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007;9:428–34
  • Eldor R, Stern E, Milicevic Z, Raz I. Early use of insulin in type 2 diabetes. Diabetes Res Clin Pract 2005;68:30–5
  • Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151–67
  • Barnett AH, Owens DR. Insulin analogues. Lancet 1997;349:47–51
  • Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193–201
  • Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decisionmaking. Curr Med Res Opin 2004;20:5–26
  • Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S27–40
  • Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002;45:S23–8
  • Eliasson B, Cederholm J, Nilsson P, Gudbjornsdottir S. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996–2003. Diabet Med 2005;22:1420–6
  • Henriksson F, Agardh CD, Berne C, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000;248:387–96
  • Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002;45:S13–17
  • Lahoz-Rallo B, Blanco-Gonzalez M, Casas-Ciria I, et al. Cardiovascular disease risk in subjects with type 2 diabetes mellitus in a population in southern Spain. Diabetes Res Clin Pract 2007;76:436–44
  • Lopez IM, Diez A, Velilla S, et al. Prevalence of diabetic retinopathy and eye care in a rural area of Spain. Ophthalmic Epidemiol 2002;9:205–14
  • Arteagoitia JM, Larranaga MI, Rodriguez JL, et al. Incidence, prevalence and coronary heart disease risk level in known type 2 diabetes: a sentinel practice network study in the Basque Country, Spain. Diabetologia 2003;46:899–909
  • Colivicchi F, Uguccioni M, Ragonese M, et al. Cardiovascular risk factor control among diabetic patients attending community-based diabetic care clinics in Italy. Diabetes Res Clin Pract 2007;75:176–83
  • The prevalence of coronary heart disease in type 2 diabetic patients in Italy: the DAI study. Diabet Med 2004;21:738–45
  • Pantoflinski J, Kieltyka A, Szybinski Z. [Visual disability due to diabetes in Cracow voivodeship]. Pol Arch Med Wewn 2001;106:847–51
  • Kinalska I., Niewada M, Glogowski C, et al. Cost of diabetes type 2 in Poland (CODIP). Diabetologia Praktyczna 2004;5:1–8
  • Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decisionmaking. Curr Med Res Opin 2004;20:5–26
  • Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523–34
  • Läkemedelsförmänsnämnden (Pharmaceutical Benefits Board of Sweden). LFN,2006. Available at: http://www.lfn.se/ [Last accessed 11 January 2004]
  • Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327–40
  • Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776–81
  • Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucoselowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–74
  • Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in healthcare evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003;6: 9–17
  • Södra Regionvardsnämnden. Universitetssjukhusen Lund och Malmö. Universitetssjukhusen Lund och Malmö 2006. Available at: http://www.srvn.org/ [Last accessed 11 January 2006]
  • The Swedish Association of Local Authorities and Regions (SALAR). Svenska Kommunföorbundet och Landstingsfördundet i Samverkan. The Swedish Association of Local Authorities and Regions (SALAR) 2006. Available at: http://sas.lf.se/ [Last accessed 11 January 2006]
  • Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. Pharmacoeconomics 2002;20(Suppl 1):43–53
  • Ghatnekar O, Persson U, Willis M, Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19:767–78
  • Institute de Salud Carlos III. Analisis coste-efectividad de diferentes estrategias para el cribado y tratamiento de la retinopatia diabetica en pacientes con diabetes mellitus. Min de Sanidad Consumo 2004;00/10116
  • SOIKOS. Centre d’Estudis En Economia De La Salut I De La Politica Social SL (SOIKOS). Base de Datos de Costes Sanitarios, Spain. 2004. Available at: www.soikos.com
  • Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmaco-economics 2003;21:651–9
  • Oliva J, Lobo F, Molina B, Monereo S. Direct healthcare costs of diabetes mellitus patients in Spain. Diabetes Care 2004;27:2616–21
  • Aros F. Guias de actuacion clinica de la Sociedad Espanola de Cardiologia en el infarto agudo de miocardio. Rev Esp Cardiol 1999;52:919–56
  • Mullins CD, Sikirica M, Seneviratne V, et al. Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 2004;22:1001–14
  • Bastida J, Aguilar S, Alvarez M, Gonzalez D. The Economic Burden of Stroke in Spain. Value in Health 2003;6:614
  • Real Decreto 1247/2002 de 3 de diciembre por el que se regula la gestion del fondo de cohesion sanitaria. BOE numero 290 ed. 2004.
  • Lamas J, Alonso M, Saavadra J, et al. Costes de la dialisis cronica en un hospital publicoL mitos y realidades. Nefrologia 2002;22:269–76
  • Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: a Spanish perspective. Nefrologia 2004;24:231–8
  • Castells X, Alonso J, Castilla M, et al. Outcomes and costs of outpatient and inpatient cataract surgery: a randomised clinical trial. J Clin Epidemiol 2001;54:23–9
  • Calle-Pascual AL, Redondo MJ, Ballesteros M, et al. Nontraumatic lower extremity amputations in diabetic and non-diabetic subjects in Madrid, Spain. Diabetes Metab 1997;23:519–23
  • Porta M, Rizzitiello A, Tomalino M, et al. Comparison of the cost-effectiveness of three approaches to screening for and treating sight-threatening diabetic retinopathy. Diabetes Metab 1999;25:44–53
  • Lucioni C, Mazzi S, Neeser K. Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. Pharmacoeconomics 2004;6: 81–93
  • Ministero della Sanita. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera di cui al DecretoMinisteriale 12 dicembre 1994. Ministero della Sanita 1997;Suppl ord. alla G.U.
  • Rudelli G, Annemans L, Spiesser J, et al. An economic evaluation of clopidigrel vs aspirin in secondaryprevention of ischemic events in high risk atherothrombotic patients in Italy. 2004
  • Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness analysis of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: the Italian perspective. PharmacoEconomics – Italian Research Articles 2004;7:41–55
  • The DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:1468–78
  • Ministero della Sanita. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio Sanitorio Nazionale e relative tariffe. Decreto Ministeriale 22 luglio 1996. Decreto Ministeriale 2004;216
  • OEMF. Informatorie Farmaceutico (marzo 2003) (Aggiornamento). Milano, 2004
  • Legge 18/1980. Indennita di accompagnamento agli invalidi civili totalmente inabili. Pubblicata su G.U. n. 44 ed. 1980
  • Kawalek P, Pilc A. Introduction to the pharmacoeconomics of diabetes care. Diabetol Pol 2003;10:429–33
  • Kawalec P, Sadowski R, Pilc A. Costs of the treatment of ischaemic heart disease in type 1 and type 2 diabetes mellitus patients in Poland. Diabetol Pol 2004;11: 125–30
  • Kawalek P, Pilc A. Costs of diabetic nephropathy in Poland. Diabetol Pol 2003;10:398–405
  • Kawalek P, Pilc A. Costs of diabetic foot in Poland. Medycyna Metaboliczna 2003;7:11–7
  • Kawalek P, Lis J, Pilc A. Costs of diabetic ischemia of lower extremities in Poland. Standardy Medyczne 2004;6:718–24
  • Kawalek P, Pilc A. Cost of diabetic retinopathy in Poland. Okulistyka 2003;(3):52–8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.